Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12659
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLouis, William Jen
dc.contributor.authorDrummer, Olaf Hen
dc.contributor.authorHowes, L Gen
dc.date.accessioned2015-05-16T02:23:10Z
dc.date.available2015-05-16T02:23:10Z
dc.date.issued1989-05-16en
dc.identifier.citationClinical and Experimental Hypertension. Part A, Theory and Practice; 11(5-6): 1075-83en
dc.identifier.govdoc2571433en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12659en
dc.description.abstractAntihypertensive drugs that interact with adrenoceptors have certain advantages and disadvantages (on the treatment of hypertension). Alpha-1 antagonists such as prazosin have favorable effects on plasma lipids but may produce excessive postural falls in blood pressure, particularly following the initial dose. Recently developed alpha-1 antagonists (doxazosin, terazosin) have longer durations of action than prazosin, allowing less frequent administration. Beta blockers may be cardioprotective but in contrast to alpha-1 antagonists tend to have adverse effects on plasma lipids. Drugs with combined beta and alpha-1 blocking activity such as labetalol have favorable metabolic effects but postural hypotension remains a problem. Recently developed drugs with different alpha-1/beta blocking ratios that differ from labetalol may prove to be more popular clinically. Several beta blockers with vasodilator activity which is not due to alpha-1 blockade have also been developed. These drugs appear to have favorable metabolic effects similar to drugs with alpha-1 blocking activity, but do not cause postural hypotension.en
dc.language.isoenen
dc.subject.otherAdrenergic alpha-Antagonists.therapeutic useen
dc.subject.otherAdrenergic beta-Antagonists.therapeutic useen
dc.subject.otherAntihypertensive Agents.adverse effects.therapeutic useen
dc.subject.otherHumansen
dc.subject.otherHypertension.blood.complications.drug therapyen
dc.subject.otherLipids.blooden
dc.subject.otherVascular Diseases.etiology.prevention & controlen
dc.subject.otherVasodilator Agents.therapeutic useen
dc.titleAlpha blockers and vasodilating beta blockers--influence on factors involved in the pathogenesis of vascular disease in patients with hypertension.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical and experimental hypertension. Part A, Theory and practiceen
dc.identifier.affiliationDepartment of Clinical Pharmacology & Therapeutics, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages1075-83en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/2571433en
dc.type.austinJournal Articleen
local.name.researcherLouis, William J
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptClinical Pharmacology and Therapeutics-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.